glp-1 receptor agonist and dpp-4 inhibitor combination not recommended The Role of Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect DPP-4 INHIBITORS - Dipeptidyl Peptidase-4
Description
doi: 10.1111/dom.13160

In May 2024, Novo Nordisk announced plans to expand production capacity for Wegovy and Ozempic by investing over USD 4.1 billion in manufacturing facilities in Denmark and the U.S

It is important to note that Zepbound is not approved to treat type 2 diabetes under this brand name, even though its active ingredient (tirzepatide) is used in diabetes care under a different brand name (Mounjaro)

Clinical relevance of antiexenatide antibodies: safety, efficacy and crossreactivity with longterm treatment

Today they stand on the threshold of helping with chronic inflammation

J., Tschp, M
